Protect eyesight and empower lives

BioTheraVision, Inc. (BTV) is a privately held, pre-clinical stage pharmaceutical company focused on developing ophthalmic therapeutics. Our approach is to repurpose known molecules through unleashing hidden potentials to treat ocular diseases where practitioners and patients are still vastly frustrated with current treatments. Our lead product candidates are BTV100 for treating ocular dry eye disease and BT300 for treating post-ocular surgery inflammation. BioTheraVision is based in Chicago, Illinois and is led by a team of pharmaceutical experts who have years of ocular drug development and drug delivery experience. BTV currently has 6 patents pending in the U.S. for its portfolio of projects.


Biotheravision, Inc.

420 North Wabash Avenue, Suite 539 | Chicago, IL 60611